References
- Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA298(15), 1763–1771 (2007).
- Deresinski S, Herrera V. Immunotherapies for Staphylococcus aureus: current challenges and future prospects. Infect. Control Hosp. Epidemiol.31(Suppl. 1), S45–S47 (2010).
- Harro JM, Peters BM, O’May GA et al. Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunol. Med. Microbiol.59, 306–323 (2010).
- Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin. Biol. Ther.10(7), 1049–1059 (2010).
- Spellberg B, Daum R. A new view on development of a Staphylococcus aureus vaccine: insights from mice and men. Hum. Vaccine.6(10), 857–859 (2010).
- Fattom AS, Sarwar J, Ortiz, A, Naso R. Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun.64(5), 1659–1665 (1996).
- Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA10, 6573–6578 (2002).
- Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macques and specific increased survival in a murine model of S. aureus sepsis. Infect. Immun.74(4), 2215–2223 (2006).
Website
- Datamonitor. Pipeline insight: nosocomial vaccines, minefield or goldmine? April 2008; DMHC2385 www.datamonitor.com/store/Product/toc.aspx?productId=DMHC2385